Literature DB >> 12419173

Blood pressure-independent impact of antihypertensive agents on cardiovascular and renal disease.

Debasish Banerjee1, Barry J Materson.   

Abstract

Reduction of elevated blood pressure clearly protects against target organ damage, but the different targets do not necessarily benefit to the same degree. There is considerable debate over whether or not there is a drug-specific benefit above and beyond that conferred by blood pressure reduction alone. We performed a Medline search to identify recent randomized clinical trials including 300 or more patients who were followed for at least 2 years. We critically reviewed these papers to find like trials for comparisons. There was too much dissimilarity to perform a meaningful meta-analysis. We found that the literature does not support a definitive conclusion either in favor of or against an overall drug-specific protective effect. However, by grouping like trials, it is possible to support an additional protective effect by angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on reducing the rate of decline in renal function and in reducing proteinuria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419173     DOI: 10.1007/s11906-002-0024-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  26 in total

1.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.

Authors:  S MacMahon; N Sharpe; G Gamble; A Clague; C N Mhurchu; T Clark; H Hart; J Scott; H White
Journal:  J Am Coll Cardiol       Date:  2000-08       Impact factor: 24.094

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

Authors: 
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

5.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group.

Authors: 
Journal:  Hypertension       Date:  1999-11       Impact factor: 10.190

8.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

9.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

10.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.